Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Anusha Kalbasi

Showing results (61-70 of 76) with videos related to

Pageof 8
Sort By:
Nature Cancer|August 9, 2021
PAK4 inhibition improves PD-1 blockade immunotherapyGabriel Abril-Rodriguez, Davis Y Torrejon, Wei Liu, et al.
Cancer Discovery|May 30, 2020
Overcoming Genetically Based Resistance Mechanisms to PD-1 BlockadeDavis Y Torrejon, Gabriel Abril-Rodriguez, Ameya S Champhekar, et al.
Nature|June 8, 2022
Potentiating adoptive cell therapy using synthetic IL-9 receptorsAnusha Kalbasi, Mikko Siurala, Leon L Su, et al.
Medrxiv : the Preprint Server for Health Sciences|November 24, 2025
Distinct Sarcoma Microenvironments Predict Benefit from Addition of Pembrolizumab to Preoperative Radiotherapy and Surgery in SU2C-SARC032Stefano Testa, Jonathon E Himes, Ajay Subramanian, et al.
Nature|November 15, 2022
Publisher Correction: Potentiating adoptive cell therapy using synthetic IL-9 receptorsAnusha Kalbasi, Mikko Siurala, Leon L Su, et al.
Biorxiv : the Preprint Server for Biology|June 9, 2023
The landscape of drug sensitivity and resistance in sarcomaAhmad Al Shihabi, Peyton J Tebon, Huyen Thi Lam Nguyen, et al.
JAMA Network Open|December 17, 2025
Five-Day Preoperative Radiation Therapy for Patients With High-Risk Soft Tissue Sarcoma: A Nonrandomized Clinical TrialJohn Nikitas, Joseph K Kendal, Ricky R Savjani, et al.
Cancer Discovery|December 2, 2016
Primary Resistance to PD-1 Blockade Mediated by JAK1/2 MutationsDaniel Sanghoon Shin, Jesse M Zaretsky, Helena Escuin-Ordinas, et al.
Nature Communications|September 26, 2025
Distinct cell state ecosystems for nodular lymphocyte-predominant Hodgkin lymphomaAjay Subramanian, Shengqin Su, Jamie Flerlage, et al.
Journal of Surgical Oncology|July 9, 2025
Incomplete Cancer Surgery Correlates With Loss of Immune Surveillance and Hyper-Progression of DiseaseStuart A Fine, Sin Yee Lim, Nicholas M Siena, et al.
Pageof 8

Showing results (61-70 of 76) with videos related to

Sort By:
Pageof 8
Nature Cancer|August 9, 2021
PAK4 inhibition improves PD-1 blockade immunotherapyGabriel Abril-Rodriguez, Davis Y Torrejon, Wei Liu, et al.
Cancer Discovery|May 30, 2020
Overcoming Genetically Based Resistance Mechanisms to PD-1 BlockadeDavis Y Torrejon, Gabriel Abril-Rodriguez, Ameya S Champhekar, et al.
Nature|June 8, 2022
Potentiating adoptive cell therapy using synthetic IL-9 receptorsAnusha Kalbasi, Mikko Siurala, Leon L Su, et al.
Medrxiv : the Preprint Server for Health Sciences|November 24, 2025
Distinct Sarcoma Microenvironments Predict Benefit from Addition of Pembrolizumab to Preoperative Radiotherapy and Surgery in SU2C-SARC032Stefano Testa, Jonathon E Himes, Ajay Subramanian, et al.
Nature|November 15, 2022
Publisher Correction: Potentiating adoptive cell therapy using synthetic IL-9 receptorsAnusha Kalbasi, Mikko Siurala, Leon L Su, et al.
Biorxiv : the Preprint Server for Biology|June 9, 2023
The landscape of drug sensitivity and resistance in sarcomaAhmad Al Shihabi, Peyton J Tebon, Huyen Thi Lam Nguyen, et al.
JAMA Network Open|December 17, 2025
Five-Day Preoperative Radiation Therapy for Patients With High-Risk Soft Tissue Sarcoma: A Nonrandomized Clinical TrialJohn Nikitas, Joseph K Kendal, Ricky R Savjani, et al.
Cancer Discovery|December 2, 2016
Primary Resistance to PD-1 Blockade Mediated by JAK1/2 MutationsDaniel Sanghoon Shin, Jesse M Zaretsky, Helena Escuin-Ordinas, et al.
Nature Communications|September 26, 2025
Distinct cell state ecosystems for nodular lymphocyte-predominant Hodgkin lymphomaAjay Subramanian, Shengqin Su, Jamie Flerlage, et al.
Journal of Surgical Oncology|July 9, 2025
Incomplete Cancer Surgery Correlates With Loss of Immune Surveillance and Hyper-Progression of DiseaseStuart A Fine, Sin Yee Lim, Nicholas M Siena, et al.
Pageof 8